		uring un	period October 1, 2021 to March 31, 2022.								Additional disclorelates to loans, entity/subsidiar transaction was	inter-corpo y. These det	rate deposits, ails need to b	, advances or in	vestments r	nade or g	ven by the list	ed
	Details of the party (listed en /subsidiary) entering into the tran	rsaction	Details of the count				Value of the related party	Value of transaction	In case monies ar party as a result of	the transaction		ake or give l leposits, adv ivestments	oans, inter- ances or			investn		
S.No.	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	transaction as approved by the audit committee (Rs in Mn)	during the reporting period (Rs in Mn)	Opening balance (Rs in Mn) (see Note 1)	Closing balance (Rs in Mn) (see Note 1)	Nature of indebtedness (loan/issuance of debt/any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter- corporate deposit/ investment	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end- usage)
	Lupin Limited		Generic Health Pty Limited, Australia		Wholly · Owned Subsidiary	Sale of Goods	343.4	343.4										1
	Lupin Limited Lupin Limited	_	Pharma Dynamics (Proprietary) Limited, South Africa Medguimica Industria Farmaceutica LTDA Brazil	+	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Sale of Goods Sale of Goods	230.1 151.2	230.1 151.2										+
	Lupin Limited	_	Hormosan Pharma GmbH, Germany	+	Wholly -Owned Subsidiary	Sale of Goods	131.5	131.5										+
	Lupin Limited		Multicare Pharmaceuticals Philippines Inc. Philippines		Subsidiary	Sale of Goods	45.3	45.3										
_		_		+														
7	Lupin Limited	_	Lupin Philippines Inc., Philippines Lupin Pharmaceuticals Inc., USA	+	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Sale of Goods Sale of Goods	64.2 7,785.9	7,785.9						_				+
8	Lupin Limited Lupin Limited		Lupin Pharma Canada Limited, Canada	_	Wholly -Owned Subsidiary	Sale of Goods	237.9	237.9		1		t						1
9	Lupin Limited		Lupin Inc., USA	\perp	Wholly -Owned Subsidiary	Sale of Goods	3,801.3	3,801.3										1
10	Lupin Limited		Lupin Atlantis Holdings SA, Switzerland		Wholly -Owned Subsidiary	Sale of Goods	519.9	519.9										
11	Lupin Limited		Lupin Healthcare (UK) Limited, UK		Wholly -Owned Subsidiary	Sale of Goods	362.6	362.6										
	Lupin Limited	+	Lupin Research Inc., USA	+	Wholly -Owned Subsidiary	Sale of Goods Income from Assignment of Rights	50.7 3.417.3	50.7 3.417.3			_		_	_	_	-		+
13	Lupin Limited		Lupin Inc., USA		Wholly -Owned Subsidiary	in IPs	3,417.3	3,417.3										
14	Lupin Limited		Medquimica Industria Farmaceutica LTDA Brazil		Wholly -Owned Subsidiary	Fees received against guarantee provided on their behalf	8.8	8.8										
15	Lupin Limited		Lupin Pharmaceuticals Inc., USA		Wholly -Owned Subsidiary	Fees received against guarantee provided on their behalf	26.3	26.3										
	Lupin Limited		Nanomi B.V., Netherlands		Wholly -Owned Subsidiary	Fees received against guarantee provided on their behalf	12.3	12.3										
17	Lupin Limited		Generic Health Pty Limited, Australia		Wholly -Owned Subsidiary	Services Rendered (Income)	1.8	1.8										
18	Lupin Limited	_	Pharma Dynamics (Proprietary) Limited, South Africa	+	Wholly - Owned Subsidiary	Services Rendered (Income)	6.4	6.4 2.3								_		+
20	Lupin Limited Lupin Limited		Hormosan Pharma GmbH, Germany Multicare Pharmaceuticals Philippines Inc. Philippines		Wholly -Owned Subsidiary Subsidiary	Services Rendered (Income) Services Rendered (Income)	2.3 1.8	1.8										
21	Lupin Limited	_	Lupin Philippines Inc., Philippines	+	Wholly -Owned Subsidiary	Services Rendered (Income)	0.5	0.5										+
	Lupin Limited	_	Lupin Pharmaceuticals Inc., USA	_	Wholly -Owned Subsidiary	Services Rendered (Income)	18.1	18.1										
23	Lupin Limited		Lupin Pharma Canada Limited, Canada		Wholly -Owned Subsidiary	Services Rendered (Income)	2.1	2.1										1
24	Lupin Limited		Lupin Inc., USA		Wholly -Owned Subsidiary	Services Rendered (Income)	2.1	2.1										
25	Lupin Limited		Lupin Atlantis Holdings SA, Switzerland		Wholly -Owned Subsidiary	Services Rendered (Income)	1.4	1.4										
26	Lupin Limited	_	Lupin Healthcare (UK) Limited, UK	_	Wholly -Owned Subsidiary	Services Rendered (Income)	2.3	2.3										
27	Lupin Limited Lupin Limited	_	Lupin Australia Pty Limited, Australia Nanomi B.V., Netherlands	_	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Services Rendered (Income) Services Rendered (Income)	0.1 1.8	0.1 1.8						-				+
28	Lupin Limited	_	Lupin Research Inc., USA	_	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Services Rendered (Income)	2.9	2.9										+
	Lupin Limited		Novel Laboratories Inc., USA		Wholly -Owned Subsidiary	Services Rendered (Income)	3.4	3.4										+
	Lupin Limited		Lupin Management Inc., USA	1	Wholly -Owned Subsidiary	Services Rendered (Income)	1.7	1,7										+
32	Lupin Limited		Lupin Europe GmbH, Germany		Wholly · Owned Subsidiary	Services Rendered (Income)	0.4	0.4										
33	Lupin Limited		Lupin Oncology Inc., USA	_	Subsidiary	Services Rendered (Income)	0.1	0.1										
34	Lupin Limited	_	Lupin Healthcare Limited, India	_	Wholly -Owned Subsidiary	Services Rendered (Income)	4.3	4.3										+
35	Lupin Limited Lupin Limited	_	Lupin Digital Health Limited, India Lupin Inc., USA	+	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Services Rendered (Income) Sale - Research Services	0.1 12.3	0.1 12.3			-							+
37	Lupin Limited		Lupin Atlantis Holdings SA, Switzerland	_	Wholly -Owned Subsidiary	Sale - Research Services	15.4	15.4										1
38	Lupin Limited		Lupin Oncology Inc., USA		Subsidiary	Sale - Research Services	803.9	803.9										
39	Lupin Limited		Medquimica Industria Farmaceutica LTDA Brazil		Wholly -Owned Subsidiary	Royalty Income	1.9	1.9										
	Lupin Limited		Generic Health Pty Limited, Australia		Wholly -Owned Subsidiary	Expenses incurred on their behalf recovered Expenses incurred on their behalf	5.3	5.3										
	Lupin Limited		Pharma Dynamics (Proprietary) Limited, South Africa	_	Wholly -Owned Subsidiary	recovered	1.6											
42	Lupin Limited Lupin Limited	1	Medquimica Industria Farmaceutica LTDA Brazil Hormosan Pharma GmbH, Germany	-	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Expenses incurred on their behalf recovered Expenses incurred on their behalf	7.1	7.1		-			-					-
44	Lupin Limited	_	Multicare Pharmaceuticals Philippines Inc. Philippines	\perp	Wholly -Owned Subsidiary Subsidiary	recovered Expenses incurred on their behalf Expenses incurred on their behalf	8.3	8.3					-					
44	Lupin Limited	-	Multicare Pharmaceuticals Philippines Inc. Philippines Lupin Philippines Inc., Philippines	-	Wholly -Owned Subsidiary	recovered Expenses incurred on their behalf Expenses incurred on their behalf	8.3 Refer Note 2	8.3 Refer Note 2										
46	Lupin Limited	+	Lupin Pharmaceuticals Inc., USA	+	Wholly -Owned Subsidiary	recovered Expenses incurred on their behalf	142.3	142.3					-					+
47	Lupin Limited		Lupin Pharma Canada Limited, Canada		Wholly -Owned Subsidiary	recovered Expenses incurred on their behalf	0.8	0.8					-					+
48	Lupin Limited	+	Lupin Inc., USA	+	Wholly -Owned Subsidiary	recovered Expenses incurred on their behalf	14.5	14.5		-			-			-		+
49	Lupin Limited	+	Lupin Atlantis Holdings SA, Switzerland	-	Wholly - Owned Subsidiary	recovered Expenses incurred on their behalf	8.4	8.4					-					+
50	Lupin Limited	+	Lupin Healthcare (UK) Limited, UK	+	Wholly -Owned Subsidiary	recovered Expenses incurred on their behalf	2.5	2,5					1					+
51	Lupin Limited	+	Nanomi B.V., Netherlands	-	Wholly -Owned Subsidiary	recovered Expenses incurred on their behalf	1.7	1.7		-			-					
52	Lupin Limited	+	Lupin Research Inc., USA	-	Wholly -Owned Subsidiary	recovered Expenses incurred on their behalf	12.4	12.4					-					
32	capin camed		copin rescored the, our		Transit, Owned Subsidiary	recovered	12.4	12.4	1	1			1	1	1			1

			period October 1, 2021 to March 31, 2022.								Additional discler relates to loans, entity/subsidiar transaction was	inter-corpo y. These det	rate deposits	advances or in	vestments r	nade or gi	en by the list	ed
	Details of the party (lister /subsidiary) entering into the	transaction	Details of the cour				Value of the related party	Value of transaction	In case monies a party as a result o	f the transaction		ake or give I leposits, adv ivestments	oans, inter- vances or			investm		
S.No.	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	transaction as approved by the audit committee (Rs in Mn)	during the reporting period (Rs in Mn)	Opening balance (Rs in Mn) (see Note 1)	Closing balance (Rs in Mn) (see Note 1)	Nature of indebtedness (loan/issuance of debt/any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter- corporate deposit/ investment	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end- usage)
53	Lupin Limited		Novel Laboratories Inc., USA		Wholly -Owned Subsidiary	Expenses incurred on their behalf	8.2	8.2										
54	Lupin Limited		Lupin Management Inc., USA		Wholly -Owned Subsidiary	recovered Expenses incurred on their behalf	9.0	9.0										+
55	Lupin Limited	_	Laboratorios Grin S.A. de CV, Mexico		Wholly -Owned Subsidiary	recovered Expenses incurred on their behalf	5.0	5.0										+
56	Lupin Limited	_	Lupin Healthcare Limited, India	_	Wholly -Owned Subsidiary	recovered Expenses incurred on their behalf	5.7	5.7										
						recovered												
57	Lupin Limited		Lupin Digital Health Limited, India		Wholly -Owned Subsidiary	Expenses incurred on their behalf recovered	12.8	12.8										
			Lupin Healthcare Limited, India		Wholly -Owned Subsidiary	Reversal of Interest provided earlier	Refer Note 3	Refer Note 3										
59	Lupin Limited		Hormosan Pharma GmbH, Germany		Wholly -Owned Subsidiary	Services Received (Expense)	25.2	25.2				1						1
61	Lupin Limited Lupin Limited		Lupin Inc., USA Lupin Atlantis Holdings SA, Switzerland	+	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Services Received (Expense) Services Received (Expense)	64.9 39.8	64.9 39.8	t	 		†	+					+
62	Lupin Limited		Lupin Pharmaceuticals Inc., USA		Wholly -Owned Subsidiary	Services Received (Expense)	45.4	45.4										=
63	Lupin Limited Lupin Limited	_	Lupin Healthcare (UK) Limited, UK Lupin Management Inc., USA	+	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Services Received (Expense) Services Received (Expense)	61.0 185.1	61.0 185.1	-			 	+					+
65	Lupin Limited		Lupin Research Inc., USA		Wholly -Owned Subsidiary	Purchase of Goods	98.0	98.0										
66	Lupin Limited		Lupin Research Inc., USA	_	Wholly -Owned Subsidiary	R & D expenses paid	242.0	242.0										
68	Lupin Limited Lupin Limited		Novel Laboratories Inc., USA Lupin Australia Pty Limited, Australia		Wholly -Owned Subsidiary Wholly -Owned Subsidiary	R & D expenses paid Expenses incurred on our behalf reimbursed & Other	15.8 8.5	15.8 8.5										
						Reimbursements												
69	Lupin Limited		Lupin Pharma Canada Limited, Canada		Wholly -Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	17.0	17.0										
70	Lupin Limited		Lupin Research Inc., USA		Wholly -Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	22.1	22.1										
71	Lupin Limited		Pharma Dynamics (Proprietary) Limited, South Africa		Wholly -Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	4.1	4.1										
72	Lupin Limited		Hormosan Pharma GmbH, Germany		Wholly -Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	10.1	10.1										
73	Lupin Limited		Lupin Inc., USA		Wholly -Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	11.6	11.6										
74	Lupin Limited		Generic Health Pty Limited, Australia		Wholly -Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	Refer Note 4	Refer Note 4										
75	Lupin Limited		Lupin Pharmaceuticals Inc., USA		Wholly -Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	96.7	96.7										
76	Lupin Limited		Lupin Europe GmbH, Germany		Wholly -Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	3.1	3.1										
77	Lupin Limited		Novel Laboratories Inc., USA		Wholly •Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	0.1	0.1										
	Lupin Limited		Lupin Management Inc., USA		Wholly -Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	1.6	1.6										
	Lupin Limited		Lupin Atlantis Holdings SA, Switzerland		Wholly -Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	0.4	0.4										
	Lupin Limited		S. N. Pharma		Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence	Purchase of goods and services	44.5	44.5										
81	Lupin Limited		Shuban Prints		Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence	Purchase of goods and services	27.6	27.6										
82	Lupin Limited		Lupin Oncology Inc., USA		Subsidiary	Investment	380.3	380.3						New				Business
83	Lupin Limited		Lupin Digital Health Limited, India		Wholly -Owned Subsidiary	Investment	220.0	220.0						New Investment				Purpose Business Purpose
0.4	Lupin Limited	-	Lupin Healthcare Limited, India	-	Wholly -Owned Subsidiary	Investment	500.0	500.0	 	+		+	+	Investment New	-	_		Purpose Business

Details of the party (listed entity / Josbadiany) entering into the transaction Name PAN Nam						Additional disci relates to loans entity/subsidia transaction was	, inter-corpo ry. These det	rate deposits ails need to b	nsactions - appl , advances or ir se disclosed onl	vestments r	nade or g	iven by the list	ted
S. N. Pharma		Value of th	Value of		are due to either of the transaction	In case any f incurred to n corporate	inancial inde	btedness is oans, inter-	Details o	f the loans, i	inter-corp investn	oorate deposits nents	, advances or
Which the KMP And Relation of Moderation o	Type of related party transaction	transaction ion approved b the audit committee (in Mn)	during the reporting	Opening balance (Rs in Mn) (see Note 1)	Closing balance (Rs in Mn) (see Note 1)	Nature of indebtedness (loan/issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan) advance/ inter- corporate deposit/ investment	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end- usage)
Which Comed Subsidiary Wholly Comed Subsidiary Wholly Comed Subsidiary Uspin Limited Uspin Limited Uspin Healthcare (UK) Limited, UK Wholly Comed Subsidiary Uspin Limited Uspin Limited Uspin Healthcare (UK) Limited, UK Wholly Comed Subsidiary Wholly Comed Subsidiary Uspin Limited Uspin Limited Uspin Limited Uspin Limited Uspin Limited Uspin Limited Uspin Healthcare (UK) Limited, UK Wholly Comed Subsidiary Wholly Comed Subsidiary Uspin Limited Uspin Limited Uspin Healthcare (UK) Limited, UK Wholly Comed Subsidiary Uspin Limited Uspin Healthcare (UK) Limited, UK Wholly Comed Subsidiary Uspin Limited Uspin Healthcare (UK) Limited, UK Wholly Comed Subsidiary Uspin Limited Uspin Healthcare (UK) Limited, UK Wholly Comed Subsidiary Uspin Limited Uspin Healthcare (UK) Limited, UK Wholly Comed Subsidiary Uspin Limited Uspin Healthcare (UK) Limited, UK Wholly Comed Subsidiary Uspin Limited Uspin Healthcare (UK) Limited, UK Wholly Comed Subsidiary Uspin Limited Uspin Healthcare (UK) Limited, UK Wholly Comed Subsidiary Uspin Limited Uspin Healthcare (UK) Limited, UK Wholly Comed Subsidiary Uspin Limited Uspin Healthcare (UK) Limited, UK Wholly Comed Subsidiary Uspin Limited Uspin Healthcare (UK) Limited, UK Wholly Comed Subsidiary Uspin Limited Uspin Healthcare (UK) Limited, UK Wholly Comed Subsidiary Uspin Limited Uspin Healthcare (UK) Limited, UK Wholly Comed Subsidiary Uspin Limited Uspin Healthcare (UK) Limited, UK Wholly Comed Subsidiary Uspin Limited Uspin Limited, Subsidiary Uspin Limited Uspin Limited Uspin Healthcare (UK) Limited, UK Wholly Comed Subsidiary Uspin Limited Uspin Limited Uspin Limited Uspin Healthcare (UK) Limited, UK Uspin Limited	f	26	.0 26.0										
Which Comed Subsidiary Wholly Owned Subsidiary Wholly Owned Subsidiary Wholly Owned Subsidiary Uspin Limited Uspin Pharma Canada Limited Uspin Limited Uspin Limited Uspin Pharma Canada Limited Uspin Limited Uspin Limited Uspin Pharma Canada Limited Limited Uspin Pharma Canada Limited Limited Limited Limited Uspin Pharma Canada Limited L	f reimbursed & Other	if 2	.1 2.1										
Wholly - Owned Subsidiary	f	21											
1	•	20											
92 Lupin Limited Medquimica Industria Farmaceutica LTDA Brazil Wholly-Owned Subsidiary 93 Lupin Limited Lupin Healthcare (UK) Limited, UK 94 Lupin Limited Lupin Healthcare (UK) Limited, UK 95 Lupin Limited Multicare Pharmaceuticals Philippines Inc. Philippines Subsidiary 96 Lupin Limited Multicare Pharmaceuticals Philippines Inc. Philippines Subsidiary 97 Lupin Limited Multicare Pharmaceuticals Philippines Inc. Philippines Subsidiary 98 Lupin Limited Lupin Philippines Inc. Philippines Myboly-Owned Subsidiary 98 Lupin Limited Lupin Philippines Inc. Philippines Myboly-Owned Subsidiary 98 Lupin Limited Lupin Philippines Inc. Philippines Myboly-Owned Subsidiary 98 Lupin Limited Lupin Indied Cenevir Health Pyr Limited, Australia Wholly-Owned Subsidiary 98 Lupin Limited Cenevir Health Pyr Limited, Australia Wholly-Owned Subsidiary 99 Lupin Limited Repairment Composition of Philippines Inc. Philippine	Corporate guarantees issued by the Company to the bankers of subsidiary company												
93 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly Owned Subsidiary 94 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly Owned Subsidiary 95 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly Owned Subsidiary 96 Lupin Limited Multicare Pharmaceuticals Philippines Inc. Philippines Subsidiary 97 Lupin Limited Lupin Philippines Inc. Philippines Subsidiary 98 Lupin Limited Lupin Philippines Inc. Philippines Wholly Owned Subsidiary 98 Lupin Limited Lupin Health Subsidiary Subsidiary 98 Lupin Limited Lupin Indied Lupin Health Subsidiary Subsidiary 99 Lupin Limited Coencir Indied Framaceutical Inc. USA Wholly Owned Subsidiary 90 Lupin Limited Coencir Indied Pharmaceutical Inc. USA Wholly Owned Subsidiary 91 Lupin Limited Lupin Health Pty Limited, Australia Wholly Owned Subsidiary 91 Lupin Limited Lupin Health Pty Limited, Subsidiary Wholly Owned Subsidiary 91 Lupin Limited Lupin Health Pty Limited, Subsidiary Wholly Owned Subsidiary 91 Lupin Limited Lupin Health Subsidiary Lupin Health Subsidiary Wholly Owned Subsidiary 91 Lupin Limited Lupin Healthcare (LIK) Limited Wholly Owned Subsidiary 91 Lupin Limited Lupin Healthcare (LIK) Limited Lupin Healthcare (LIK) Limited Lupin Healthcare (LIK) Limited Lupin Healthcare (LIK) Limited Lupin Limited Lupin Healthcare (LIK) Limited Lupin Limited Lupin Limited Lupin Healthcare Lupin Limited Lup	Withdrawal of corporate guarantees given by the Company to the bankers of subsidiary company												
193 Lupin Limited	Withdrawal of corporate guarantees given by the Company to the bankers of subsidiary company												
Second	Guarantees issued by the Compan on behalf of subsidiary company for contractual obligations	v											
Subsidiary Sub	Guarantees issued by the Compan on behalf of subsidiary company for contractual obligations		.6 64.6										
97 Uppin Limited Novel Laboratories Inc. USA Wholly- Comed Subsidiary 99 Uppin Limited Uppin Inc. USA Wholly- Comed Subsidiary 99 Uppin Limited Generic Health Pty Limited, Australia Wholly- Comed Subsidiary 100 Uppin Limited Generic Health Pty Limited, Australia Wholly- Comed Subsidiary 101 Uppin Limited Homosan Pharma Gmbl, Germany Wholly- Comed Subsidiary 101 Uppin Limited Liupin Pharmaceuteak Inc. USA Wholly- Comed Subsidiary 101 Uppin Limited Liupin Pharmaceuteak Inc. USA Wholly- Comed Subsidiary 101 Uppin Limited Liupin Pharmaceuteak Inc. USA Wholly- Comed Subsidiary 101 Uppin Limited Liupin Pharmaceuteak Inc. USA Wholly- Comed Subsidiary 101 Uppin Limited Liupin Pharmaceuteak Inc. USA Wholly- Comed Subsidiary 101 Uppin Limited Liupin Pharmaceuteak Inc. UK Molly- Comed Subsidiary 101 Uppin Limited Liupin Pharmaceuteak Inc. UK Molly- Comed Subsidiary 101 Uppin Limited Liupin Pharmaceuteak Inc. UK Molly- Comed Subsidiary 101 Uppin Limited Liupin Pharmaceuteak Inc. UK Molly- Comed Subsidiary 101 Uppin Limited Liupin Pharmaceuteak Inc. UK Molly- Comed Subsidiary 101 Uppin Limited Liupin Pharmaceuteak Inc. UK Molly- Comed Subsidiary 101 Uppin Limited Liupin Pharmaceuteak Inc. UK Molly- Comed Subsidiary 101 Uppin Limited Liupin Pharmaceuteak Inc. UK Molly- Comed Subsidiary 101 Uppin Limited Liupin Pharmaceuteak Inc. UK Molly- Comed Subsidiary 101 Uppin Limited Liupin Pharmaceuteak Inc. UK Molly- Comed Subsidiary 101 Uppin Limited Liupin Pharmaceuteak Inc. UK Molly- Comed Subsidiary 101 Uppin Limited Liupin Pharmaceuteak Inc. UK Molly- Comed Subsidiary 101 Uppin Limited Liupin Limited Liupin Molly- Comed Subsidiary 101 Uppin Limited Liupin Limited Liupin Molly- Comed Subsidiary 101 Uppin Limited Liupin Molly- Comed Subsidiar	Receivables Receivables Receivables			339.i 41.0 220.i	52.5	5							‡
199 Lippin Limited Generic Health Pty Limited, Australia Wholly- Comed Subsidiary	Receivables			3.	9 5.8	3							
100 Lippi Limited Pharma Dynamics (Proprietary) Limited, South Africa Wholly-Coared Subsidiary	Receivables Receivables			2,583.9 288.4	9 6,842.5 8 264.4		+	+		-	_	+	+
101 Lipsi Limited Hormosan Pharma GmbH, Germany Wholly- Oxened Subsidiary	Receivables			153.	2 173.7								
103 Lippi Limited Lippi Research Inc., LSA Wholly- Comed Subsidiary	Receivables		_	3. 15,866.4			_	_	_	_		_	+
105 Lippin Limited Mediguamica Industria Farmaceutica LTDA Brazil Wholly-Owned Subsidiary 106 Lippin Limited Lippin Hallist Holdings SA, Sutretand Wholly-Owned Subsidiary 107 Lippin Limited Lippin Hallist Holdings SA, Sutretand Wholly-Owned Subsidiary 108 Lippin Limited Lippin Hallist Holdings SA, Sutretand Wholly-Owned Subsidiary 108 Lippin Limited Lippin Europe GmBH, Germany Wholly-Owned Subsidiary 100 Lippin Limited Lippin Europe GmBH, Germany Wholly-Owned Subsidiary 101 Lippin Limited Lippin Hallistare Limited, India Wholly-Owned Subsidiary 102 Lippin Limited Lippin Hallistare Limited, India Wholly-Owned Subsidiary 103 Lippin Limited Lippin Martialia Pty-Limited, Justicalia Wholly-Owned Subsidiary 104 Lippin Limited Lippin Martialia Pty-Limited, Justicalia Wholly-Owned Subsidiary 105 Lippin Limited Lippin Martialia Pty-Limited, Justicalia Wholly-Owned Subsidiary 106 Lippin Limited Lippin Bolgal Health Limited, India Wholly-Owned Subsidiary 107 Lippin Limited Lippin Bolgal Health Limited, Justicalia Wholly-Owned Subsidiary 108 Lippin Limited Lippin Bolgal Health Limited, Justicalia Wholly-Owned Subsidiary 109 Lippin Limited Lippin Bolgal Health Limited, Justicalia Wholly-Owned Subsidiary 109 Lippin Limited Lippin Hallistare Limited, Justicalia Wholly-Owned Subsidiary 109 Lippin Limited Lippin Hallistare Lippin Limited, Lippin Limited Lippin Hallistare Lippin Lippin Lippin Lippin Limited Lippin Hallistare Lippin Lippin Lippin Lippin Limited Lippin Hallistare Lippin Limited, Lippin Lippin Lippin Limited Lippin Hallistare Lippin Lippin Lippin Lippin Lippin Lippin Lippin Lippin Limited Lippin Hallistare Lippin Lippin Lippin Lippin Lippin Lippin Lippin Lippin Lippin Lippi	Receivables Receivables	_	1	15,866.4			+	+		+		_	+
105 Lupin Limited Lupin Atlantis Holdings S.S. Switzerland Wholly-Comed Subsidiary	Receivables			350.	5 374.3								
107 Lippi Limited Laboratorios Grin S.A. de CV, Mexico Wholly-Comed Subsidiary Wholly-Comed Subsidiary Wholly-Comed Subsidiary Wholly-Comed Subsidiary Wholly-Comed Subsidiary Wholly-Comed Subsidiary Lippi Limited Lippi Decology Inc., USA Subsidiary Wholly-Comed Subsidiary Lippi Limited Lippi Mastlinear Limited, India Wholly-Comed Subsidiary Lippi Limited Lippi Mastlinear Limited, Australia Wholly-Comed Subsidiary Lippi Limited Lippi Mastlinear Pty Limited, Australia Wholly-Comed Subsidiary Lippi Limited Lippi Mastlinear Pty Limited, Australia Wholly-Comed Subsidiary Lippi Limited Lippi Bolgal Health Limited, India Wholly-Comed Subsidiary Lippi Limited Lippi Bolgal Health Limited, Lipsi Limited, Comed Subsidiary Lippi Limited Lippi Bolgal Health Limited, Australia Wholly-Comed Subsidiary Lippi Limited Lippi Bolgal Health Limited, Australia Wholly-Comed Subsidiary Lippi Limited Lippi Mastlinear Lippi Rospia Limited, Australia Wholly-Comed Subsidiary Lippi Limited Lippi Mastlinear Lippi Australia Wholly-Comed Subsidiary Lippi Limited Lippi Australia Wholly-Comed Subsidiary Lippi Limited Lippi Mastlinear Lippi Limited Lippi Australia Wholly-Comed Subsidiary Lippi Limited Lippi Limited Lippi Mastlinear Lippi Limited Lippi Mastlinear Lippi Limited Lippi Mastlinear Lippi Limited Lippi Limited Lippi Limited Lippi Mastlinear Lippi Limited Lipp	Receivables		1	301.6				_				1	
108 Lipin Limited Lipin Europe GmBH, Germany Wholly Coxend Subsidiary	Receivables Receivables		+	191.	9 356.3		+	+		1		+	+
109 Lippi Limited Lippi Oscology Inc., USA Subsidiary	Receivables			0.	1 0.2			1					+
111 Lipon Limited Manomi & V., Rebherlands Wholly- Cowned Subsidiary 113 Lipon Limited Lipon Australia Wholly- Cowned Subsidiary 113 Lipon Limited Lipon Management Ne., USA Wholly- Cowned Subsidiary 115 Lipon Limited Lipon Bologiss, Limited, India Wholly- Cowned Subsidiary 115 Lipon Limited Generic Health Fry Limited, Australia Wholly- Cowned Subsidiary 117 Lipon Limited Homosan Pharma GmbH, Germany Wholly- Cowned Subsidiary 118 Lipon Limited Lipon Australia Wholly- Cowned Subsidiary 119 Lipon Limited Lipon Australia Wholly- Cowned Subsidiary 121 Lipon Limited Lipon Healthcare (UK) Limited, UK Wholly- Cowned Subsidiary 121 Lipon Limited Lipon Healthcare (UK) Limited, UK Wholly- Cowned Subsidiary 123 Lipon Limited Lipon Management Ne, USA Wholly- Cowned Subsidiary 123 Lipon Limited Lipon Management Re, USA Wholly- Cowned Subsidiary 241 Lipon Limited Lipon Management Re, USA Wholly- Cowned Subsidiary <	Receivables			538.	7 812.6								
112 Ligni Limited Ligni Australia Pty United, Australia Wholly- Comed Subsidiary	Receivables	_	+	5.			-	-		-	-		+
131 Lipp in Limited Lipp in Management Nr., USA Wholty- Owned Subsidiary 115 Lipp in Limited Lipp in Morph Health Limited, India Wholty- Owned Subsidiary 115 Lipp in Limited Lipp in Morph Gologis Limited, India Wholty- Owned Subsidiary 117 Lipp in Limited Homosan Pharma GmbH, Germany Wholty- Owned Subsidiary 118 Lipp in Limited Lipp in Australia Wholty- Owned Subsidiary 119 Lipp in Limited Lipp in Australia Wholty- Owned Subsidiary 20 Lipp in Limited Lipp in Marse GmbH, Germany Wholty- Owned Subsidiary 21 Lipp in Limited Lipp in Marse GmbH, Germany Wholty- Owned Subsidiary 21 Lipp in Limited Lipp in Marse GmbH, Germany Wholty- Owned Subsidiary 22 Lipp in Limited Lipp in Marse GmbH, Germany Wholty- Owned Subsidiary 23 Lipp in Limited Lipp in Marse GmbH, Germany Wholty- Owned Subsidiary 24 Lipp in Limited Lipp in Marse GmbH, Germany Wholty- Owned Subsidiary	Receivables Receivables		+ :	7. Refer Note 5	Refer Note 6	1		1				1	+
115 Upon Limited Upon Explosits. Limited, India Wholity-Owned Subsidiary 117 Upon Limited Generic Health Pty Limited, Australia Wholity-Owned Subsidiary 117 Upon Limited Homosan Fharma Gmibl, Germany Wholity-Owned Subsidiary 118 Upon Limited Lupin Australia Pty Limited, Australia Wholity-Owned Subsidiary 121 Lupin Limited Lupin Health Lame (UK) Wholity-Owned Subsidiary 121 Lupin Limited Lupin Healthcare (UK) Wholity-Owned Subsidiary 122 Lupin Limited Lupin Healthcare (UK) Wholity-Owned Subsidiary 123 Lupin Limited Lupin Management Inc., USA Wholity-Owned Subsidiary 124 Lupin Limited Lupin Management Inc., USA Wholity-Owned Subsidiary	Receivables			15.5	5 3.1								
16 Lupin Limited Generic Health Pty Limited, Australia Wholly, Owned Subsidiary	Receivables	_	+	0.	2 0.2		-	1		-		-	+
117 Lippin Limited Hormosan Pharma GmbH, Germany Wholly- Comed Subsidiary 118 Lippin Limited Lippin Astralis Foldings SA, Swreterland Wholly- Comed Subsidiary 119 Lippin Limited Lippin Asstralia PY, Limited, Australia Wholly- Comed Subsidiary 121 Lippin Limited Lippin Faregore GmbH, Germany Wholly- Comed Subsidiary 121 Lippin Limited Lippin Healthcare (UK) Limited, UK Wholly- Comed Subsidiary 122 Lippin Limited Lippin Management Rus, USA Wholly- Comed Subsidiary 123 Lippin Limited Lippin Management Rus, USA Wholly- Comed Subsidiary 124 Lippin Limited Lippin Management Rus, USA Wholly- Comed Subsidiary 125 Lippin Limited Lippin Management Rus, USA Wholly- Comed Subsidiary	Receivables Payables		+ :	0.				1				1	+
119 Lupin Limited Lupin Australia PV, Limited, Australia Wholly- Cowned Subsidiary 201 Lupin Limited Lupin Europe GmbH, Germany Wholly- Cowned Subsidiary 211 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly- Cowned Subsidiary 212 Lupin Intel Lupin Management Ne, USA Wholly- Cowned Subsidiary 213 Lupin Limited Lupin Management Ne, USA Wholly- Cowned Subsidiary 214 Lupin Limited Lupin Phara Canada Limited, Canada Wholly- Cowned Subsidiary	Payables			22.2	2 32.0								
120 Lupin Limited Lupin Europe GmBH, Germany Wholly-Owned Subsidian 121 Lupin Limited Lupin Mealthcare (UK) Limited, UK Wholly-Owned Subsidian 122 Lupin Limited Lupin Management Lee, USA Wholly-Owned Subsidian 123 Lupin Limited Lupin Management Lee, USA Wholly-Owned Subsidian 124 Lupin Limited Lupin Management Lee, USA Wholly-Owned Subsidian	Payables		+ -	26.4	4 40.7	1	_	_		 		_	+
121 Lypin Limited Uppin Healthcare (UK) Limited, UK Wholly- Owned Subsidiary 123 Lippin Limited Uppin May Wholly- Owned Subsidiary 123 Lippin Limited Uppin Management Inc., USA Wholly- Owned Subsidiary 241 Lippin Limited Uppin Management Intel, Canada Wholly- Owned Subsidiary	Payables Payables		+ -	18.9		-	+	+		†		+	+
123 Lupin Limited Lupin Management Inc., USA Wholly -Owned Subsidiary 124 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary	Payables			25.7	7 47.9	9							
124 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly - Owned Subsidiary	Payables		4	78.8									
22.4 Lapin chinica Lupin rhamia canada dinited, canada Wholly -Owned Subsidiary	Payables Payables			94.6			1	+		 	-	+	+
125 Lupin Limited Lupin Pharmaceuticals Inc., USA Wholly -Owned Subsidiary	Payables			1,228.1				1					
126 Lupin Limited Lupin Philippines Inc., Philippines Wholly -Owned Subsidiary 127 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary	Payables Payables		-	300.:	0.1 2 291.4								

			e period October 1, 2021 to March 31, 2022.			I					Additional disclerelates to loans, entity/subsidiar transaction was	inter-corpo y. These det undertaker	rate deposits tails need to b	, advances or ir	vestments n	nade or g	ven by the list	ted
	Details of the party (listed ent /subsidiary) entering into the trans	saction	Details of the coun	erpart _\	,		Value of the related party	Value of	In case monies at party as a result of		In case any fi incurred to m corporate e in	ake or give l	loans, inter-	Details o	f the loans, i	nter-corp investn		s, advances or
S.No.	Name		Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	transaction as approved by the audit committee (Rs in Mn)	transaction during the reporting period (Rs in Mn)	Opening balance (Rs in Mn) (see Note 1)	Closing balance (Rs in Mn) (see Note 1)	Nature of indebtedness (loan/issuance of debt/any other etc.)	Cost	Tenure	Nature (loan) advance/ inter- corporate deposit/ investment	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by th ultimate recipient of funds (end- usage)
128	Lupin Limited		Medquimica Industria Farmaceutica LTDA Brazil		Wholly · Owned Subsidiary	Payables	-		13.8									
	Lupin Limited		Novel Laboratories Inc., USA		Wholly -Owned Subsidiary	Payables	-		5.5									
	Lupin Limited	+	Pharma Dynamics (Proprietary) Limited, South Africa	+	Wholly -Owned Subsidiary	Payables	-		6.5					-		_		
122	Lupin Limited Lupin Limited	+	Lupin Pharmaceuticals Inc., USA Lupin Australia Pty Limited, Australia	+	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Investment Investment	-		13.8 33.3	13.8		_						+
133	Lupin Limited	_	Lupin Atlantis Holdings SA, Switzerland	+	Wholly -Owned Subsidiary	Investment		- :	32,805.6	32,805.6				1				_
134	Lupin Limited		Nanomi B.V., Netherlands		Wholly -Owned Subsidiary	Investment			50,885.2	50,885.2								\perp
135	Lupin Limited		Lupin Healthcare Limited, India		Wholly -Owned Subsidiary	Investment	-		581.7	1,081.7								
136	Lupin Limited	1	Lupin Biologics Limited, India	_	Wholly -Owned Subsidiary	Investment	-		1.0	1.0		1			1	_		
	Lupin Limited	+	Lupin Oncology Inc., USA	+	Subsidiary Subsidiary	Investment	-		747.6		-		+		-	_		+
138	Lupin Limited Lupin Limited	+	Lupin Digital Health Limited, India Lupin Healthcare (UK) Limited, UK	+	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Investment Corporate guarantees issued by	-		0.1	400.1		_	+	_	 	_		+
133	Eupin Ellineed		Eupin readicate (ON) Limited, ON		Wilding Cowied Subsidiary	the Company to the bankers of subsidiary company				04.0								
140	Lupin Limited		Medquimica Industria Farmaceutica LTDA Brazil		Wholly -Owned Subsidiary	Corporate guarantees issued by the Company to the bankers of subsidiary company	-	-	-	5,840.2								
141	Lupin Limited		Lupin Pharmaceuticals Inc., USA		Wholly -Owned Subsidiary	Corporate guarantees issued by the Company to the bankers of subsidiary company	-	-	-	28,895.9								
142	Lupin Limited		Nanomi B.V., Netherlands		Wholly -Owned Subsidiary	Guarantees issued by the Company on behalf of subsidiary company for contractual obligations	-	-	-	5,075.1								
143	Lupin Limited		Mr. Nilesh D. Gupta		Key Management Personnel	Remuneration paid	36.4	36.4										
144	Lupin Limited	_	Mr. Ramesh Swaminathan	_	Key Management Personnel	Remuneration paid	42.0	42.0										
145	Lupin Limited	+	Mr. R. V. Satam	+	Key Management Personnel	Remuneration paid	4.5	4.5										
146	Lupin Limited Lupin Limited	+	Mrs. Manju D. Gupta Dr. Kamal K. Sharma	+	Non- Executive Director Non- Executive Director	Commission / Sitting Fees Commission / Sitting Fees	3.3 5.1	3.3 5.1				_				_		+
148	Lupin Limited		Dr. Kamal K. Sharma	\top	Non- Executive Director	Settlement of liabilities by entity on	4.0	4.0										
140	Locate Heathard	+	Dr. Kamal K. Sharma	+	Non- Executive Director	behalf of related party	4.5	4.5				_				_		
150	Lupin Limited Lupin Limited		Mr. Jean-Luc Belingard	+	Independent Director	Value of Perquisites provided Commission / Sitting Fees	4.5 3.9	3.9						1				+
151	Lupin Limited	+	Ms. Christine Ann Mundkur	\top	Independent Director	Commission / Sitting Fees	4.0	4.0										_
152	Lupin Limited		Mr. K.B.S. Anand	\top	Independent Director	Commission / Sitting Fees	3.9	3.9										1
153	Lupin Limited		Dr. Punita Kumar-Sinha		Independent Director	Commission / Sitting Fees	4.0	4.0										
154	Lupin Limited	_	Mr. Mark D. Mcdade		Independent Director	Commission / Sitting Fees	3.9	3.9										
155			Lupin Human Welfare and Research Foundation		Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence	Donation	236.9	236.9										
	Lupin Limited		Mata Shree Gomati Devi Jan Seva Nidhi		Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence	Donation	8.6	8.6										
157	Lupin Limited		Polynova Industries Limited		Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence	Rent received	1.1	1.1										
158	Lupin Limited		Polynova Industries Limited		Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence	Deposit Received			0.1	0.1								
159	Lupin Limited		Zyma Properties Pvt. Limited		Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence	Deposit Paid against office premises			29.0	29.0								
160	Lupin Limited		Shuban Prints		Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence	Payables			1.0	2.5								

			eriod October 1, 2021 to March 31, 2022.								Additional disclo relates to loans, entity/subsidiar transaction was	inter-corpo y. These det	rate deposits	, advances or in	vestments r	nade or gi	ven by the list	ed
	Details of the party (listed entity /subsidiary) entering into the transacti	ion	Details of the counter		Relationship of the counterparty		Value of the related party	Value of transaction	In case monies as party as a result of Opening balance	the transaction	In case any fi incurred to m corporate o ir	ake or give le deposits, adv nvestments	oans, inter- ances or			investm	orate deposits ents Secured/	
S.No.	Name PA	AN N	ame	PAN	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	transaction as approved by the audit committee (Rs in Mn)	during the reporting period (Rs in Mn)	(Rs in Mn) (see Note 1)	Closing balance (Rs in Mn) (see Note 1)	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter- corporate deposit/ investment	Interest Rate (%)	Tenure	secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end- usage)
161	Lupin Limited	S.	N. Pharma		Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence	Payables			3.4	6.7								
162 I	Lupin Limited	Ti	eam Lease Services Limited		Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence	Payables			Refer Note 7	Refer Note 7								
163 I	Lupin Management Inc., USA	N	1s. Vinita Gupta		Key Management Personnel	Remuneration paid	73.0	73.0										1
164 I	Lupin Atlantis Holdings SA,	L	upin Pharmaceuticals Inc., USA		Fellow Subsidiary	Sale of Goods	NA	(216.6)										
165 I	Switzerland Lupin Inc., USA	L	upin Pharma Canada Limited, Canada	\vdash	Fellow Subsidiary	Sale of Goods	NA	(0.1)					1					
166	Novel Laboratories Inc., USA	L	ıpin Inc., USA		Fellow Subsidiary	Sale of Goods	NA	2,807.1										
167	Lupin Inc., USA		upin Pharmaceuticals Inc., USA		Fellow Subsidiary	Sale of Goods	NA	6,386.0										
	Lupin Research Inc., USA		upin Inc., USA	_	Fellow Subsidiary	Sale - Research Services	NA	717.0 300.5					-					+
170	Novel Laboratories Inc., USA Lupin Research Inc., USA		ıpin Inc., USA ıpin Atlantis Holdings SA, Switzerland		Fellow Subsidiary	Sale - Research Services Sale - Research Services	NA NA	300.5 25.8					-					+
	Lupin Research Inc., USA		anomi B.V Netherlands	-	Fellow Subsidiary Fellow Subsidiary	Sale - Research Services	NA NA	68.1					_					+
172 I	Lupin Pharmaceuticals Inc., USA	b	upin Atlantis Holdings SA, Switzerland		Fellow Subsidiary	Services Rendered (Income)	NA	0.7										
	Lupin Pharmaceuticals Inc., USA		upin Pharma Canada Limited, Canada		Fellow Subsidiary	Services Rendered (Income)	NA	0.7										
	Lupin Inc., USA		upin Atlantis Holdings SA, Switzerland	_	Fellow Subsidiary	Services Rendered (Income)	NA	9.9										
	Lupin Inc., USA Lupin Management Inc., USA		ıpin Pharma Canada Limited, Canada eneric Health Pty Limited, Australia	-	Fellow Subsidiary Fellow Subsidiary	Services Rendered (Income)	NA NA	17.5					-					+
	Lupin Management Inc., USA		aboratorios Grin S.A. de CV. Mexico		Fellow Subsidiary	Services Rendered (Income)	NA NA	22.7										+
178	Lupin Pharmaceuticals Inc., USA		ppin Management Inc., USA		Fellow Subsidiary	Services Rendered (Income)	NA NA	5.5										
179	Lupin Pharmaceuticals Inc., USA	L	upin Research Inc., USA		Fellow Subsidiary	Services Rendered (Income)	NA	3.0										
180 I	Lupin Pharmaceuticals Inc., USA	N	ovel Laboratories Inc., USA		Fellow Subsidiary	Services Rendered (Income)	NA	4.3										
	Lupin Inc., USA		ipin Management Inc., USA		Fellow Subsidiary	Services Rendered (Income)	NA	21.9										
	Lupin Inc., USA		ipin Pharmaceuticals Inc., USA		Fellow Subsidiary	Services Rendered (Income)	NA	53.8										
183	Lupin Inc., USA		upin Research Inc., USA ovel Laboratories Inc., USA		Fellow Subsidiary	Services Rendered (Income) Services Rendered (Income)	NA NA	18.8 26.7					-					+
185	Lupin Inc., USA Lupin Research Inc., USA		over Laboratories Inc., USA upin Inc., USA		Fellow Subsidiary Fellow Subsidiary	Services Rendered (Income)	NA NA	105.3								_		+
186	Lupin Pharmaceuticals Inc., USA		upin Inc., USA		Fellow Subsidiary	Services Rendered (Income)	NA NA	150.8										
	Lupin Management Inc., USA		upin Atlantis Holdings SA, Switzerland		Fellow Subsidiary	Services Rendered (Income)	NA	25.8										
	Lupin Management Inc., USA		ıpin Pharma Canada Limited, Canada		Fellow Subsidiary	Services Rendered (Income)	NA	4.2										
	Lupin Management Inc., USA Lupin Management Inc., USA	- 1	ledquimica Industria Farmaceutica LTDA Brazil fulticare Pharmaceuticals Philippines Inc. Philippines		Fellow Subsidiary Fellow Subsidiary	Services Rendered (Income) Services Rendered (Income)	NA NA	19.5 14.2										+
191	Lupin Management Inc., USA	N	anomi B.V., Netherlands	\vdash	Fellow Subsidiary	Services Rendered (Income)	NA NA	6.8				1	+	_	-			+
192	Lupin Management Inc., USA		apin Inc., USA		Fellow Subsidiary	Services Rendered (Income)	NA NA	76.7										
193	Lupin Management Inc., USA	L	upin Pharmaceuticals Inc., USA		Fellow Subsidiary	Services Rendered (Income)	NA	27.4										
194	Lupin Management Inc., USA	L	upin Research Inc., USA		Fellow Subsidiary	Services Rendered (Income)	NA	8.2										
195	Lupin Management Inc., USA	N	ovel Laboratories Inc., USA		Fellow Subsidiary	Services Rendered (Income)	NA	32.2										
	Lupin Atlantis Holdings SA,	Н	ormosan Pharma GmbH, Germany		Fellow Subsidiary	Services Rendered (Income)	NA	15.8										
197	Switzerland Lupin Atlantis Holdings SA, Switzerland	b	upin Healthcare (UK) Limited, UK		Fellow Subsidiary	Services Rendered (Income)	NA	2.7										1
198 I	Lupin Atlantis Holdings SA,	N	anomi B.V., Netherlands		Fellow Subsidiary	Services Rendered (Income)	NA	2.4										T
199 I	Switzerland Lupin Atlantis Holdings SA,	٦,	upin Inc., USA		Fellow Subsidiary	Services Rendered (Income)	NA	1.5					 					_
200 I	Switzerland Lupin Atlantis Holdings SA, Switzerland	+	harma Dynamics (Proprietary) Ltd. South Africa		Fellow Subsidiary	Services Rendered (Income)	NA NA	2.9										
- 1																		

Details	s of Related Parties transactions duri	ing th	e period October 1, 2021 to March 31, 2022.									, inter-corpo y. These det	rate deposits,	advances or in	vestments i	made or g	e related party t given by the liste porting period w	ed
	Details of the party (listed entit /subsidiary) entering into the transa	ction	Details of the counte				Value of the related party	Value of transaction	In case monies a party as a result o	of the transaction	1	ake or give l deposits, adv nvestments	oans, inter- vances or			investn		
S.No.	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	transaction as approved by the audit committee (Rs in Mn)	during the reporting period (Rs in Mn)	Opening balance (Rs in Mn) (see Note 1)	Closing balance (Rs in Mn) (see Note 1)	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter- corporate deposit/ investment	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end- usage)
202	Lupin Atlantis Holdings SA,		Lupin Healthcare (UK) Limited, UK		Fellow Subsidiary	Interest income on	NA	5.0									1	1
203	Switzerland Lupin Atlantis Holdings SA,		Nanomi B.V., Netherlands		Fellow Subsidiary	Intercorporate Loans Interest income on	NA	1.3										
	Switzerland				Tellow Substation y	Intercorporate Loans												
204	Lupin Atlantis Holdings SA, Switzerland		Lupin Inc., USA		Fellow Subsidiary	Interest income on Intercorporate Loans	NA	247.1										
205	Nanomi B.V., Netherlands		Lupin Healthcare (UK) Limited, UK		Fellow Subsidiary	Interest income on	NA NA	Refer Note 8										1
206	Nanomi B.V., Netherlands	\vdash	Medquimica Industria Farmaceutica LTDA Brazil	+	Fellow Subsidiary	Intercorporate Loans Interest income on	NA NA	9.1				+	1				+	+
207	Hormosan Pharma GmbH,	_	Lupin Europe GmbH, Germany	-	Fellow Subsidiary	Intercorporate Loans	NA NA	0.5										
	Hormosan Pharma GmbH, Germany	L		L	reliow Subsidiary	Interest income on Intercorporate Loans												
208	Lupin Inc., USA		Novel Laboratories Inc., USA		Fellow Subsidiary	Interest income on Intercorporate Loans	NA	14.8										
209	Multicare Pharmaceuticals Philippines Inc. Philippines		Lupin Philippines Inc., Philippines		Fellow Subsidiary	Rent Received	NA	0.2										
210	Multicare Pharmaceuticals		Lupin Philippines Inc., Philippines		Fellow Subsidiary	Purchase of Goods	NA NA	48.1									 	
211	Philippines Inc. Philippines Generic Health Pty Limited,		Lupin Australia Pty Limited, Australia		Fellow Subsidiary	Purchase of Goods	NA NA	0.2									-	
212	Australia Generic Health Pty Limited,		Lupin Atlantis Holdings SA, Switzerland		Fellow Subsidiary		NA NA	Refer Note 9										_
	Australia				· ·	Services Received (Expense)												
213	Lupin Atlantis Holdings SA, Switzerland		Hormosan Pharma GmbH, Germany		Fellow Subsidiary	Services Received (Expense)	NA	70.8										
214	Lupin Atlantis Holdings SA, Switzerland		Lupin Healthcare (UK) Limited, UK		Fellow Subsidiary	Services Received (Expense)	NA	15.4										
215	Lupin Atlantis Holdings SA, Switzerland		Lupin Pharma Canada Limited, Canada		Fellow Subsidiary	Services Received (Expense)	NA	175.1										
216	Lupin Atlantis Holdings SA, Switzerland		Lupin Pharmaceuticals Inc., USA		Fellow Subsidiary	Services Received (Expense)	NA	0.7										
217	Lupin Atlantis Holdings SA, Switzerland		Lupin Inc., USA		Fellow Subsidiary	Services Received (Expense)	NA	9.9										
218	Lupin Atlantis Holdings SA,		Lupin Management Inc., USA		Fellow Subsidiary	, , ,	NA	25.8									-	-
219	Switzerland Lupin Atlantis Holdings SA,	<u> </u>	Hormosan Pharma GmbH, Germany	-	Fellow Subsidiary	Services Received (Expense)	NA NA	0.1									₩	
	Switzerland				Fellow Subsidiary	Services Received (Expense)												
220	Lupin Atlantis Holdings SA, Switzerland		Lupin Europe GmbH, Germany		Fellow Subsidiary	Services Received (Expense)	NA	21.6	·									
221	Lupin Atlantis Holdings SA,		Lupin Research Inc., USA	T	Fellow Subsidiary	Services Received (Expense)	NA	0.1									T	
222	Switzerland Nanomi B.V., Netherlands		Lupin Management Inc., USA		Fellow Subsidiary	Services Received (Expense)	NA NA	6.8										1
223	Nanomi B.V., Netherlands	\vdash	Hormosan Pharma GmbH, Germany	+	Fellow Subsidiary		NA NA	2.3				+	+				+	+
224	Hormosan Pharma GmbH,		Lupin Europe GmbH, Germany	-	Fellow Subsidiary	Services Received (Expense)	NA NA	1.2				1						+
	Germany			_	· ·	Services Received (Expense)											<u></u>	
225 226	YL Biologics Ltd., Japan Lupin Atlantis Holdings SA,	-	Lupin Atlantis Holdings SA, Switzerland Lupin Research Inc., USA	\vdash	Jointly Controlled Entity Fellow Subsidiary	Services Received (Expense)	NA NA	7.1 25.8		1						-	+	+
	Switzerland Nanomi B.V., Netherlands	_	Lupin Research Inc., USA	-	Fellow Subsidiary	R & D expenses paid R & D expenses paid	NA NA	68.1			-		1			_	+	+
	Hormosan Pharma GmbH,		Lupin Europe GmbH, Germany	t	Fellow Subsidiary Fellow Subsidiary	Service Charges received	NA NA	23.2									 	+
229	Germany Generic Health Pty Limited,	\vdash	Lupin Australia Pty Limited, Australia	+	Fellow Subsidiary	-			-	0.1		1	1	-		-	+	+
230	Australia Lupin Pharmaceuticals Inc., USA		Lupin Pharma Canada Limited, Canada	1	Fellow Subsidiary	Receivable			1.1			-	-		-	-	+	1
231	Lupin Pharmaceuticals Inc., USA		Lupin Atlantis Holdings SA, Switzerland	1	· ·	Receivable			(0.6			1						
		_			Fellow Subsidiary	Receivable												
232 233	Lupin Research Inc., USA Lupin Research Inc., USA		Nanomi B.V., Netherlands Lupin Atlantis Holdings SA, Switzerland	+	Fellow Subsidiary Fellow Subsidiary	Receivable Receivable			18.8				1			-		+
234	Lupin Inc., USA		Lupin Pharma Canada Limited, Canada		Fellow Subsidiary	Receivable			0.1	1 0.1								
235	Lupin Inc., USA		Lupin Oncology Inc., USA	1	Fellow Subsidiary	Receivable			8.4									
	Lupin Inc., USA Lupin Management Inc., USA		Lupin Atlantis Holdings SA, Switzerland Medquimica Industria Farmaceutica LTDA Brazil	1	Fellow Subsidiary Fellow Subsidiary	Receivable Receivable	-		3.2			1	-			-	+	+
	Lupin Management Inc., USA		Multicare Pharmaceuticals Philippines Inc. Philippines		Fellow Subsidiary	Receivable			6.5									
	Lupin Management Inc., USA		Laboratorios Grin S.A. de CV, Mexico		Fellow Subsidiary	Receivable			15.8									
240	Lupin Management Inc., USA		Nanomi B.V., Netherlands		Fellow Subsidiary	Receivable			4.5	3.9								

41 Lu 42 Lu 43 Lu 44 Y 45 Lu 50 46 Lu 50 47 Lu 50 48 Lu 50 50 50 50 51 51 Lu 50 50 50 50 50 50 50 50 50 50 50 50 50	Details of the party (listed entity subsidiary) entering into the transaction of the tran	PAN N	Details of the counter lame eeneric Health Pty Limited, Australia pupin Pharma Canada Limited, Canada		Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	Value of the related party transaction as	Value of	In case monies ar party as a result of		In case any fir incurred to ma corporate d	ake or give lo	oans, inter-	Details of	the loans, ir	nter-corp	orate deposits, ients	advances or
No. 441 Lu 42 Lu 43 Lu 44 Y1 45 Lu 50 46 Lu 50 47 Lu 50 50 50 Lu 50 50 50 66 66 66 66 66 66 66 66 66 66 66 66 66	upin Management Inc., USA upin Management Inc., USA upin Management Inc., USA UB Biologics Ltd., Japan upin Atlants Hodings SA, upin Atlants Hodings SA, upin Atlants Hodings SA, witzerland upin Atlants Hodings SA,	G Lu Lu	eneric Health Pty Limited, Australia	PAN	with the listed entity or its	Type of related party transaction	transaction as	transaction				vestments	mices of					
42	upin Management Inc., USA upin Management Inc., USA L Biologics Ltd., Japan upin Atlantis Holdings SA, witzerland upin Atlantis Holdings SA, witzerland upin Atlantis Holdings SA,	lu lu					approved by the audit committee (Rs in Mn)	during the reporting period (Rs in Mn)	Opening balance (Rs in Mn) (see Note 1)	Closing balance (Rs in Mn) (see Note 1)	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter- corporate deposit/ investment	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end- usage)
143 Lu 144 145 Lu 145	upin Management Inc., USA E Biologics Ltd., Japan upin Atlantis Holdings SA, witzerland upin Atlantis Holdings SA, witzerland upin Atlantis Holdings SA,	lı Lı	pin Pharma Canada Limited, Canada		Fellow Subsidiary	Receivable			8.3	10.7								
244 YLL 25 Lu 25 Lu 26 Lu 27 Lu 27 Lu 28 L	L Biologics Ltd., Japan upin Atlantis Holdings SA, witzerland upin Atlantis Holdings SA, witzerland upin Atlantis Holdings SA, witzerland upin Atlantis Holdings SA,	Lu		_	Fellow Subsidiary	Receivable			2.5	1.1				\perp			ـــــــ	
45 Lu Sv 46 Lu Sv 47 Lu Sv 48 Lu Sv 49 Lu Sv 50 Lu Sv 51 Lu Sv 52 Lu Sv 53 Hi Gr 54 Lu	upin Atlantis Holdings SA, witzerland upin Atlantis Holdings SA, witzerland upin Atlantis Holdings SA,		upin Atlantis Holdings SA, Switzerland	+	Fellow Subsidiary	Receivable			1.5 20.4	19.0 20.4								
Sv. 446 Lu Sv. 447 Lu Sv. 448 Lu Sv. 449 Lu Sv. 550 Lu Sv. 551 Lu Sv. 552 Lu Sv. 553 Hi Gri	witzerland upin Atlantis Holdings SA, witzerland upin Atlantis Holdings SA,	1"	upin Atlantis Holdings SA, Switzerland Iormosan Pharma GmbH, Germany	+	Jointly Controlled Entity Fellow Subsidiary	Receivable			173.4	38.3								+
247 Lu Sv 248 Lu Sv 249 Lu Sv 250 Lu Sv 251 Lu Sv 252 Lu Sv 253 Hi Gi 254 Lt	upin Atlantis Holdings SA,	L	upin Healthcare (UK) Limited, UK		Fellow Subsidiary	Receivable Receivable			58.1	110.7							 	+-
148 Lu Sv 149 Lu Sv 150 Lu Sv 151 Lu Sv 152 Lu Sv 153 Hi Gr 154 Lt	witzerland	N	lanomi B.V., Netherlands	+	Fellow Subsidiary				0.8	1.8								+
250 Lu Sv 251 Lu Sv 252 Lu Sv 253 Hi G	upin Atlantis Holdings SA,	_	upin Inc., USA	-	Fellow Subsidiary	Receivable Receivable			Refer Note 10	1.6								+
50 Lu 50 Sv 51 Lu 52 Lu 52 Sv 53 Hi 60	witzerland upin Atlantis Holdings SA,		upin Pharma Canada Limited, Canada	+	Fellow Subsidiary	Receivable			990.8	1,059.3			 					+
51 Lu Sv 52 Lu Sv 53 Hr 60	witzerland upin Atlantis Holdings SA,		harma Dynamics (Proprietary) Ltd. South Africa		Fellow Subsidiary	Receivable			1.3	1.7								+
52 Lu 52 Sv 53 Hi 60	witzerland upin Atlantis Holdings SA,		upin Europe GmbH, Germany	+	Fellow Subsidiary				Refer Note 11	-			\vdash	\vdash			<u> </u>	+
53 He G 54 Lu	witzerland upin Atlantis Holdings SA,		upin Pharmaceuticals Inc., USA	+	Fellow Subsidiary	Receivable Receivable			50.0	-			_					+-
54 Lu	witzerland Iormosan Pharma GmbH,	L	upin Europe GmbH, Germany		Fellow Subsidiary	Receivable			37.6	27.5								+
	ermany upin Pharmaceuticals Inc., USA	L	upin Research Inc., USA		Fellow Subsidiary	Receivable			8.9	4.7								+
:55 Lu	upin Pharmaceuticals Inc., USA	N	lovel Laboratories Inc., USA		Fellow Subsidiary	Receivable			6.3	-								+
56 Lu	upin Pharmaceuticals Inc., USA	L	upin Inc., USA		Fellow Subsidiary	Receivable			4,808.1	11,072.4								
57 Lu	upin Pharmaceuticals Inc., USA	L	upin Management Inc., USA		Fellow Subsidiary	Receivable			5.8	2.2								
58 Lu	upin Research Inc., USA	lı	upin Management Inc., USA		Fellow Subsidiary	Receivable				3.9								
59 N	lovel Laboratories Inc., USA		upin Pharmaceuticals Inc., USA		Fellow Subsidiary	Receivable			16.1	3.3								
	lovel Laboratories Inc., USA		upin Inc., USA	_	Fellow Subsidiary	Receivable			2,240.2	1,235.7							<u> </u>	
61 Lu	upin Inc., USA upin Inc., USA		upin Research Inc., USA lovel Laboratories Inc., USA	+	Fellow Subsidiary Fellow Subsidiary	Receivable Receivable			115.8 49.5	158.5							├──	
63 Lu	upin Inc., USA upin Inc., USA		upin Management Inc., USA	+	Fellow Subsidiary Fellow Subsidiary	Receivable			19.3	-			-				-	
64	upin Management Inc., USA		upin Pharmaceuticals Inc., USA		Fellow Subsidiary	Receivable			17.0	-								
65 Lu	upin Management Inc., USA	L	upin Research Inc., USA		Fellow Subsidiary	Receivable			10.1	-								
	upin Management Inc., USA		lovel Laboratories Inc., USA		Fellow Subsidiary	Receivable			13.5	16.6								
	upin Management Inc., USA	L	upin Inc., USA		Fellow Subsidiary	Receivable			(40.0)	5.1								
Au	ieneric Health Pty Limited, ustralia	Si	outhern Cross Pharma, Australia		Fellow Subsidiary	Investment			-	1,665.9								
69 Lu Sv	upin Atlantis Holdings SA, witzerland		aboratorios Grin S.A. de CV, Mexico		Fellow Subsidiary	Investment			6,149.6	6,149.6								
Sv	upin Atlantis Holdings SA, witzerland		upin Europe GmbH, Germany		Fellow Subsidiary	Investment			40.9	40.9								
Sv	upin Atlantis Holdings SA, witzerland		upin Healthcare (UK) Limited, UK		Fellow Subsidiary	Investment			279.7	279.7 250.8				\Box				
Sv	upin Atlantis Holdings SA, witzerland		upin Pharma Canada Limited, Canada		Fellow Subsidiary	Investment			250.8				<u> </u>					
Sv	upin Atlantis Holdings SA, witzerland upin Atlantis Holdings SA,		Medquimica Industria Farmaceutica LTDA Brazil	-	Fellow Subsidiary	Investment			4,170.3 20,784.4	4,170.3 21,222.0			<u> </u>					—
Sv	witzerland		upin Inc., USA		Fellow Subsidiary	Investment				· ·				\perp			<u> </u>	↓
	lanomi B.V., Netherlands lanomi B.V., Netherlands		ormosan Pharma GmbH, Germany harma Dynamics (Proprietary) Ltd. South Africa		Fellow Subsidiary Fellow Subsidiary	Investment Investment			1,207.7 6,878.8	1,207.7 6,878.8								+
77 N:	lanomi B.V., Netherlands		upin Mexico S.A. de C.V. Mexico	+	Fellow Subsidiary	Investment			52.2	52.2		-	\vdash		-			+
	lanomi B.V., Netherlands		upin Philippines Inc., Philippines	1	Fellow Subsidiary	Investment			59.9	59.9								+
79 Na	lanomi B.V., Netherlands	G	ieneric Health SDN.BHD.Malaysia		Fellow Subsidiary	Investment			8.2	9.3								
	lanomi B.V., Netherlands		upin Inc., USA		Fellow Subsidiary	Investment			60,232.0	60,232.0								
02	lanomi B.V., Netherlands		Medquimica Industria Farmaceutica LTDA Brazil Multicare Pharmaceuticals Philippines Inc. Philippines	+	Fellow Subsidiary Fellow Subsidiary	Investment Investment			1,316.7 250.6	1,316.7 250.6			\vdash					-
83 N	Janomi B.V., Netherlands	- 1		-		Imagguight												

DC tuli		ing unc	period October 1, 2021 to March 31, 2022.								Additional disclos relates to loans, in entity/subsidiary. transaction was u	nter-corpor These deta	rate deposits ails need to b	advances or in	vestments r	nade or g	iven by the liste	ed
	Details of the party (listed entity /subsidiary) entering into the transa	ction	Details of the counte				Value of the related party	Value of	In case monies a party as a result o		In case any fina incurred to mal corporate de inv	ke or give k	oans, inter-	Details o	f the loans, i	inter-corp investn	orate deposits, nents	. advances or
S.No.	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	transaction as approved by the audit committee (Rs in Mn)	transaction during the reporting period (Rs in Mn)	Opening balance (Rs in Mn) (see Note 1)	Closing balance (Rs in Mn) (see Note 1)	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter- corporate deposit/ investment	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end- usage)
284	Lupin Inc., USA		Lupin Pharmaceuticals Inc., USA		Fellow Subsidiary	Investment			610.4	610.4								1
285	Lupin Inc., USA		Novel Laboratories Inc., USA		Fellow Subsidiary	Investment			6,172.6	6,172.6								
	Lupin Inc., USA		Lupin Research Inc., USA		Fellow Subsidiary	Investment			769.1	769.1								
287	Lupin Inc., USA		Novel Laboratories Inc., USA		Fellow Subsidiary	Loan			1,187.7	-				Interco loan	0.025	-	Unsecured	Business Purpose
288	Lupin Inc., USA		Lupin Research Inc., USA		Fellow Subsidiary	Loan			-	909.5				Interco loan		-	Unsecured	Business Purpose
289	Generic Health Pty Limited, Australia		Lupin Australia Pty Limited, Australia		Fellow Subsidiary	Loan			20.3	2.8				Interco loan			Unsecured	Business Purpose
290	Generic Health Pty Limited, Australia		Southern Cross Pharma, Australia		Fellow Subsidiary	Loan			-	17.0				Interco loan			Unsecured	Business Purpose
291	Lupin Atlantis Holdings SA, Switzerland		Laboratorios Grin S.A. de CV, Mexico		Fellow Subsidiary	Loan			576.5	439.9				Interco loan	5.32	9 yrs	Unsecured	Business Purpose
292	Lupin Atlantis Holdings SA,		Lupin Healthcare (UK) Limited, UK		Fellow Subsidiary	Loan			799.0	795.6				Interco loan	1.25	2 yrs	Unsecured	Business
293	Switzerland Lupin Atlantis Holdings SA, Switzerland		Nanomi B.V., Netherlands		Fellow Subsidiary	Loan				341.5				Interco loan	1.4	3 yrs	Unsecured	Purpose Business Purpose
294	Lupin Atlantis Holdings SA,		Lupin Inc., USA		Fellow Subsidiary	Loan			-	2,273.8				Interco loan	1.45	3 yrs	Unsecured	Business
295	Switzerland Nanomi B.V., Netherlands		Medquimica Industria Farmaceutica LTDA Brazil		Fellow Subsidiary	Loan			593.8	606.3				Interco loan	3.00	1 yr	Unsecured	Purpose Business
296	Hormosan Pharma GmbH, Germany		Lupin Europe GmbH, Germany		Fellow Subsidiary	Loan			129.1	126.3				Interco loan	EEMI + 75 bpa	2 yrs	Unsecured	Purpose Business Purpose
297	Lupin Atlantis Holdings SA, Switzerland		Lupin Healthcare (UK) Limited, UK		Fellow Subsidiary	Other Current Assets			2.1	-								
298	Lupin Atlantis Holdings SA, Switzerland		Laboratorios Grin S.A. de CV, Mexico		Fellow Subsidiary	Other Current Assets			7.8	-								
299	Lupin Atlantis Holdings SA, Switzerland		Lupin Inc., USA		Fellow Subsidiary	Preference Dividend Receivable			233.8									
300	Multicare Pharmaceuticals Philippines Inc. Philippines		Lupin Management Inc., USA		Fellow Subsidiary	Payables			6.5	6.4								
301	Multicare Pharmaceuticals Philippines Inc. Philippines		Lupin Philippines Inc., Philippines		Fellow Subsidiary	Payables			254.1	255.2								
302	Generic Health Pty Limited, Australia		Lupin Australia Pty Limited, Australia		Fellow Subsidiary	Payables			1.5	0.1			1					
303	Generic Health Pty Limited, Australia		Lupin Management Inc., USA		Fellow Subsidiary	Payables			8.3	10.7								
304	Generic Health Pty Limited, Australia		Lupin Atlantis Holdings SA, Switzerland		Fellow Subsidiary	Payables			6.7									1
305	Lupin Atlantis Holdings SA, Switzerland		Lupin Europe GmbH, Germany		Fellow Subsidiary	Payables			7.3	19.5								
306	Lupin Atlantis Holdings SA,		Lupin Healthcare (UK) Limited, UK		Fellow Subsidiary	Payables			11.8	5.2								
307	Switzerland Lupin Atlantis Holdings SA,		Lupin Inc., USA	t	Fellow Subsidiary	Payables			3.2	6.5								<u> </u>
308	Switzerland Lupin Atlantis Holdings SA,	-	Lupin Management Inc., USA	T	Fellow Subsidiary	Payables			1.5	19.0								†
309	Switzerland Lupin Atlantis Holdings SA,		Lupin Pharma Canada Limited, Canada	+	Fellow Subsidiary	Payables	1		84.9	88.4			<u> </u>					+
310	Switzerland Lupin Atlantis Holdings SA,		Lupin Pharmaceuticals Inc., USA	T	Fellow Subsidiary	Payables			(0.6)	171.0								<u> </u>
311	Switzerland Lupin Atlantis Holdings SA,		Lupin Research Inc., USA	T	Fellow Subsidiary	Payables			7.1	14.9								†
312	Switzerland Lupin Atlantis Holdings SA,	\vdash	Hormosan Pharma GmbH, Germany	+	Fellow Subsidiary	Payables			84.4	(12.7)			 					1
313	Switzerland Nanomi B.V., Netherlands	\vdash	Hormosan Pharma GmbH. Germany	+	Fellow Subsidiary	Payables			-	2.3			-		-		-	+
	Nanomi B.V., Netherlands		Lupin Management Inc., USA	+	Fellow Subsidiary	Payables			4.5				+					+

D	tails c	of Related Parties transactions durin	ig the	period October 1, 2021 to March 31, 2022.															
Г												Additional disclo	osure of relat	ed party tran	nsactions - app	licable only	in case the	related party t	ransaction
												relates to loans,	inter-corpor	ate deposits,	, advances or ir	vestments	made or g	iven by the lists	ed
												entity/subsidiar	y. These deta	ils need to b	e disclosed onl	y once, duri	ing the rep	orting period w	hen such
\perp												transaction was	undertaken.						
												In case any fir	nancial indeb	tedness is					
		Details of the party (listed entity		Details of the counter						In case monies ar	re due to either	incurred to m	ake or give lo	oans, inter-	Details o	f the loans,	inter-corp	orate deposits,	advances or
	- 1/	subsidiary) entering into the transac	tion	Details of the counter	rparty					party as a result of	f the transaction	corporate d	deposits, adv	ances or			investn	nents	
								Value of the related party	Value of			in	nvestments						
		Name I	DA N	Name	DAN	Relationship of the counterparty	1	transaction as	transaction	Opening balance	Closing	Nature of	Cost	Tenure	Nature (loan)	Interest	Tenure	Secured/	Purpose for
١.	No.	· I	A14	Name		with the listed entity or its	Type of related party transaction		during the	(Rs in Mn)	balance (Rs in	indebtedness	Cost	renare	advance/	Rate (%)	renure	unsecured	which the
1					1	subsidiary	Type of related party transaction	the audit	reporting	(see Note 1)	Mn)	(loan/issuance			inter-				funds will be
					1	,		committee (Rs	period	((see Note 1)	of debt/ any			corporate				utilised by the
					1			in Mn)	(Rs in Mn)			other etc.)			deposit/				ultimate
					1										investment				recipient of
					1														funds (end-
					1														usage)
1	15 N	Nanomi B.V., Netherlands		Lupin Research Inc., USA		Fellow Subsidiary	Payables			18.8	39.9								
- [3	16 H	Hormosan Pharma GmbH,		Lupin Europe GmbH, Germany		Fellow Subsidiary	Payables			3.6	5.7								
-1	- 1	Cormanu			1						1	1	1	1	1	1	1	1	1

- Germany

 Notes:

 1) Receivables / Payables represents combined balance against Sales / Purchase of Goods and debit / credit notes pertaining to various services / reimbursement of expenses. Hence shown separately.
 2) The value of transaction is R 64,3687
 3) The value of transaction is R 64,3687
 3) The value of transaction is R 64,3687
 5) The value of closing balance is R 3,5918
 6) The value of closing balance is R 3,5918
 7) The value of closing balance is R 3,2078
 8) The value of closing balance is R 3,23,078
 8) The value of closing balance is R 3,23,003
 9) The value of closing balance is R 3,23,003
 9) The value of closing balance is R 3,23,003
 10) The value of closing balance is R 3,23,003
 11) The value of closing balance is R 3,2,601
 11) The value of closing balance is R 3,2,661